Table 5

Companion reports for primary studies included in evidence syntheses

Reports in bold italics provided analyzable crossover data

Main reportCompanion reportsSIP/FDA reports
Geiss (2005) 119 Geiss (2006) 200
Pearson (2005)117Pearson (2005)201Pearson (2006)202Denke (2006)203
Capuzzi (2003)155Capuzzi (2004)204
Masana (2005)167Gagne (2002)131Simons (2004)205
Davidson (2002)130Sager (2003)206FDA Extension Trial Report98
Nordoy (2001)165Nordoy (2003)207
Chan (2002)107Chan (2002)208Chan (2002)209Chan (2006)210
Nordoy (1998)177Nordoy (2000)211
Simons (1998)198Simons (1998)212
Wiklund (1993)134Vanhanen (1995)213Wiklund (1996)214
Insull (2004)182Insull (2005)215
Bays (2003)49Bays (2003)216Bays (2003)217Bays (2005)218
Taylor (2004)196Taylor (2007)219
Athyros (2005)160Athyros (2006)220
Ballantyne (2005)118Pearson (2007)221Abate (2008)222
Ballantyne (2003)126Ballantyne (2004)223
Bays (2004)154Ose (2007)147
Catapano (2006)193Abate (2008)222
Goldberg (2006)144Guyton (2008)153
Yokoyama (2007)141Tanaka (2008)224
Goldberg (2004)48FDA Extension Trial Report99
Knapp (2001)172FDA Companion Report100
Gagne (2002)132FDA Companion Report101
Melani (2003)127FDA Companion Report102
Kerzner (2003)129FDA Companion Report103

From: 3, Results

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.